The technology, which competes with ST in the market for processing sexed bovine semen, was being sold by ABS Global Inc under the IntelliGen brand.
A jury at the US District Court for the Western District of Wisconsin ruled that ABS will have to pay a royalty of US$2.60 for each straw of sexed semen produced in the US that were part of the three infringed patents.
ABS has now modified the IntelliGen technology to avoid continued infringement.
The litigation forms part of a long-running dispute between ABS Global Inc, Inguran, and Cytonome over the development and launch of Genus' sexed semen technology.
In 2014, a court ruled that Inguran and Cytonome wilfully maintained an illegal monopoly in the US market for sexed bovine semen processing. The court found that ABS had infringed a patent and this was sent back for a retrial.
Inguran, and Cytonome filed patent infringement claims against Genus and ABS Global in 2017, claiming ABS’s technology infringed upon seven patents. Ahead of the second trial, ABS successfully demonstrated non-infringement of five of the seven patents and dismissed the trade secret and breach of contract claims.
"IntelliGen provides farmers and bull studs with a novel technology for sexing bovine semen that focuses on fertility outcomes and has seen a rapid uptake since its launch in 2017,” Genus said.
“ABS will continue to expand and commercialise its IntelliGen technology providing customers and third party bull studs with an alternative service provider, increased competition and improved fertility outcomes.”